Fifty years with aspirin and platelets

Area of Science:

• Pharmacology
• Biochemistry
• Cardiovascular Medicine

Background:

• Sir John Vane's 1971 paper proposed aspirin inhibits prostaglandin synthesis, explaining its effects on pain, fever, and inflammation.
• Bengt Samuelsson's work on the cyclooxygenase pathway in platelets provided further mechanistic insight.
• Early research focused on prostaglandin synthesis inhibition by aspirin.

Purpose of the Study:

• To investigate the clinical pharmacology of cyclooxygenase inhibition by aspirin.
• To characterize the role of platelet thromboxane A2 biosynthesis in aspirin's effects.
• To provide a personal account of aspirin research over 50 years, culminating in its antiplatelet applications.

Main Methods:

• Measuring platelet thromboxane A2 biosynthesis.
• Clinical research investigating cyclooxygenase inhibition.
• Observational and participatory research over five decades.

Main Results:

• Established low-dose aspirin as a potent inhibitor of platelet function.
• Demonstrated aspirin's critical role in antiplatelet therapy.
• Confirmed aspirin's mechanism involving cyclooxygenase inhibition.

Conclusions:

• Low-dose aspirin is a life-saving antiplatelet drug.
• Aspirin remains a cornerstone of modern antithrombotic therapy.
• The research journey exemplifies a success story in independent scientific investigation.